1. Home
  2. PKE vs FULC Comparison

PKE vs FULC Comparison

Compare PKE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Aerospace Corp.

PKE

Park Aerospace Corp.

HOLD

Current Price

$33.86

Market Cap

463.2M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$6.28

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKE
FULC
Founded
1954
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.2M
467.8M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
PKE
FULC
Price
$33.86
$6.28
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
175.8K
569.9K
Earning Date
05-15-2026
04-27-2026
Dividend Yield
1.53%
N/A
EPS Growth
N/A
N/A
EPS
0.37
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$89.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.30
$5.89
52 Week High
$35.86
$15.74

Technical Indicators

Market Signals
Indicator
PKE
FULC
Relative Strength Index (RSI) 55.19 38.86
Support Level $32.00 $6.36
Resistance Level $35.58 $7.09
Average True Range (ATR) 1.47 0.40
MACD -0.22 -0.09
Stochastic Oscillator 61.25 28.00

Price Performance

Historical Comparison
PKE
FULC

About PKE Park Aerospace Corp.

Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: